About Us

Board of Directors

Dr. Ehud Geller, Chairman

Dr. Ehud Geller, Chairman - Founder & Managing Partner, Medica Venture Partners

Dr. Ehud Geller has served as the Chairman of the Regentis Board of Directors since 2007. He served as the General Partner of Medica Venture Partners.  Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President and CEO of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel Institute, Philadelphia. Since 1995, he has been the General Partner of Medica Venture Partners.  Mr. Geller was selected to serve on the board of directors as Chairman due to his significant experience leading and growing companies in the pharmaceutical industry and his significant leadership experience.

Mr. Jeff Dykan

Mr. Jeff Dykan - Managing Partner, SCP Vitalife

Mr. Jeff Dykan has served on the Regentis Board of Directors since 2005. He was appointed by Regentis’ shareholder SCP Vitalife. Since 2002, Mr. Dykan has been a director of Vitalife Partners Management LP, the general partner of Vitalife, and since 2007, has been a director of its successor fund, SCP Vitalife GP, the corporate general partner of the common general partner of SCP Vitalife Partners II L.P. and its affiliate SCP Vitalife Partners (Israel) II L.P. He has also served as a managing member of SCP Vitalife Management Company, LLC and SCP Vitalife Management Israel Ltd., which by contract provides certain management services to the common general partner of SCP Vitalife. Prior to joining Vitalife, from 2001 to 2002, Mr. Dykan was the Chairman and Chief Executive Officer of BitBand Inc., formerly a provider of content management and delivery systems, specializing in video on demand for IPTV. Mr. Dykan serves currently as Chairman of ReWalk Robotics and was a member of the American Institute of Certified Public Accountants from 1982 through 2021 and holds a B.Sc. in accounting and management and an M.B.A. in computer applications, both from New York University.

Mr. Pini Ben-Elazar (designate)

Mr. Pini Ben-Elazar (designate) - CEO of Mor Research Applications, Tech Transfer Office of Clalit Health Services

Mr. ben-Elazar is a very experienced executive as a CEO and as a director with over 25 years of successful experience in the healthcare industry. He is a change and growth leader providing fiscal, strategic and operations leadership in uniquely challenging situations, and is a professional negotiator harnessing effective and creative thinking and communicating skills. Mr. Ben-Elazar currently serves as the CEO of Mor Research Applications, Tech Transfer Office of Clalit Health Services in Israel since 2003. He is also a director in numerous healthcare companies among them: Ceretrieve, Enox, DreamMed Diabetes, Data2Life, NGS, APX ophthalmology, Zebra Medical Vision, and Galil Ofek. Mr. Ben-Elazar holds an MBA from Johnson & Wales University, Providence, RI since 1996, a B.Sc in Hospitality Management, Johnson & Wales University, Providence, RI, and completed the studies of the 8400 Health Network Leadership Program, Harvard Business School, in 2019.

Dr. Susan Alpert (designate)

Dr. Susan Alpert (designate) - Principal of SFADC LLC

Dr. Alpert is currently the principal of SFADC LLC (aka SFA Regulatory, LLC) since 2019, a one person firm focused on the strategies needed to place medical devices and other medical products into the global market. She was a Corporate Senior Vice President for Global Regulatory at Medtronic, Inc. and prior to that VP Regulatory Science at C.R. Bard, Inc. She previously worked at the U.S. FDA where she held a variety of management positions in the centers dealing with drugs, devices and radiological health, and foods. She was Director of the Office of Device Evaluation from 1993-1999. Dr. Alpert is a microbiologist and pediatrician with a specialty in infectious diseases. She completed her undergraduate degree at Barnard College, Columbia University in New York City, holds a master’s degree and Ph.D. in Biomedical Sciences from New York University and a medical degree from the University of Miami (Florida). Dr. Alpert is a member of several non-profit and for-profit boards.

Keith C. Valentine, Independent Director

Keith C. Valentine, Independent Director - President, Chief Executive Officer & Director of SeaSpine

Mr. Keith Valentine has served on the Regentis Board of Directors since 2015. Mr. Valentine currently serves as President, Chief Executive Officer and as a director of SeaSpine since 2015. Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive, Inc., from 2007 to 2015 and as President from 2004 to 2007, prior to which he served in various senior executive roles in Marketing, Development and Operations since joining the company in 2001. Previously, Mr. Valentine was Vice President of Marketing at ORATEC Interventions, Inc., which was acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek including Vice President of Marketing for the Thoracolumbar Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing. Mr. Valentine received a B.B.A. in Management and Biomedical Sciences from Western Michigan University.